- Home
- FGBI vs INZY Comparison
FGBI vs INZY Comparison
Compare FGBI & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGBI
- INZY
- Stock Information
- Founded
- FGBI 1934
- INZY 2015
- Country
- FGBI United States
- INZY United States
- Employees
- FGBI N/A
- INZY N/A
- Industry
- FGBI Savings Institutions
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- FGBI Finance
- INZY Health Care
- Exchange
- FGBI Nasdaq
- INZY Nasdaq
- Market Cap
- FGBI 158.1M
- INZY 188.2M
- IPO Year
- FGBI N/A
- INZY 2020
- Fundamental
- Price
- FGBI $10.21
- INZY $1.35
- Analyst Decision
- FGBI
- INZY Strong Buy
- Analyst Count
- FGBI 0
- INZY 8
- Target Price
- FGBI N/A
- INZY $17.75
- AVG Volume (30 Days)
- FGBI 10.1K
- INZY 770.8K
- Earning Date
- FGBI 02-03-2025
- INZY 03-11-2025
- Dividend Yield
- FGBI 3.82%
- INZY N/A
- EPS Growth
- FGBI N/A
- INZY N/A
- EPS
- FGBI 0.85
- INZY N/A
- Revenue
- FGBI $95,480,000.00
- INZY N/A
- Revenue This Year
- FGBI N/A
- INZY N/A
- Revenue Next Year
- FGBI $5.12
- INZY N/A
- P/E Ratio
- FGBI $12.51
- INZY N/A
- Revenue Growth
- FGBI 0.27
- INZY N/A
- 52 Week Low
- FGBI $8.39
- INZY $1.32
- 52 Week High
- FGBI $15.25
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- FGBI 30.09
- INZY 20.16
- Support Level
- FGBI $10.21
- INZY $1.32
- Resistance Level
- FGBI $10.85
- INZY $3.18
- Average True Range (ATR)
- FGBI 0.34
- INZY 0.26
- MACD
- FGBI -0.03
- INZY -0.13
- Stochastic Oscillator
- FGBI 0.00
- INZY 1.61
About FGBI First Guaranty Bancshares Inc.
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.